Overview of the Market:
The Middle-East & Africa nuclear medicine diagnostic market is estimated at $1.32 billion in 2018 and is expected to reach $3.49 billion by 2023, at a compound annual growth rate (CAGR) of 21.45%.Nuclear medicine is a branch of medicine that uses radiation to deliver information about the functioning of a person's specific organs or to treat a disease. In most cases, the information will assist the physicians to make a quick, accurate diagnosis of the patient's illness.
Till recent days, SPECT imaging was the most conventional modality for nuclear medicine applications. However, the trend is soon going to see a downside owing to shortage of molybdenum-99 isotope which in turn will lead to deficiency of Technetium-99. Therefore, PET imaging products which include hybrid PET-CT scanners are expected to account for a potentially hefty market share in the near future.
The emerging market will be a fusion of nuclear imaging with different diagnostic imaging products such as SPECT/CT, PET/CT and MRI/PET. This provides full range of imaging scans through the same unit and at the same time. PET market is expected to witness faster growth compared to SPECT imaging as it delivers higher resolution images and the lack of availability of technetium-99m is forcing the industry to look for alternative diagnostic procedures
Increasing usage of SPECT and PET in medical diagnostics, rising awareness among people about radiopharmaceuticals, and the easy availability of radiopharmaceuticals are some of the key driving factors associated with the growth of the market. However, shorter half- life of radioisotopes, regulatory guidelines, high capital investment and reimbursement issues are the major factors acting as hurdles for the nuclear medicine market growth.
The Nuclear Medicine Market is segmented into two major segments SPECT (Technetium-99m (TC-99m), Iodine (I-123) Thallium-201 (TL-201) and others) and PET (Rubidium-82 (RB-82), Fluorine-18, and others). By application,the market is categorized into SPECT (lymphoma, cardiology,neurology,thyroid and others) and PET(cardiology,oncology, neurology and others).
Geographical Analysis:
Furthermore, on the basis of geography, the Middle-East & Africa Market is analysed under various regions namely, UAE, Saudi Arabia, Israel and South Africa.
Key Players in this Market:
Some of the key players influencing the Middle-East & Africa nuclear medicine market are Cardinal Health, Inc., Bracco Imaging S.p.A,GE Healthcare,Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc.,Advanced Accelerator Applications S.A., IBA Molecular Imaging, and Mallinckrodt plc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 SPECT
5.1.1.1 Technetium-99m
5.1.1.2 Thallium-201
5.1.1.3 Gallium-67
5.1.1.4 Iodine-23
5.1.1.5 Others
5.1.2 PET
5.1.2.1 Fluorine-18
5.1.2.2 Rubidium-82
5.1.2.3 Others
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.5.1 UAE
6.5.2 Saudi Arabia
6.5.3 Israel
6.5.4 South Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cardinal Health Inc.
8.3 Bracco Imaging S.p.A
8.4 Eczacibasi-Monrol Nuclear Products
8.5 Nordion, Inc.
8.6 Bayer Healthcare
8.7 Lantheus Medical Imaging, Inc.
8.8 Advanced Accelerator Applications S.A.
8.9 IBA Molecular Imaging
8.10 Mallinckrodt plc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
